Table 2.

Logistic regression analysis for predictors of response according to PET4 criteria in rituximab-treated DLBCL patients (n = 97)

OR95% CIP
Univariate analysis    
 AUC1 ≥9400 mg × h per liter 3.47 1.52-8.21 .004 
 TMTV0, cm3 (×10−20.91 0.82-0.98 .033 
 IPI (3-4) 0.36 0.15-0.82 .017 
 Chemotherapy (CHOP) 0.95 0.42-2.14 .90 
 Male 0.56 0.24-1.27 .17 
 Age, y 1.04 1.003-1.08 .036 
Final model*    
 AUC1 ≥9400 mg × h per liter 5.56 2.19-15.62 .0006 
 Age, y 1.06 1.02-1.10 .004 
OR95% CIP
Univariate analysis    
 AUC1 ≥9400 mg × h per liter 3.47 1.52-8.21 .004 
 TMTV0, cm3 (×10−20.91 0.82-0.98 .033 
 IPI (3-4) 0.36 0.15-0.82 .017 
 Chemotherapy (CHOP) 0.95 0.42-2.14 .90 
 Male 0.56 0.24-1.27 .17 
 Age, y 1.04 1.003-1.08 .036 
Final model*    
 AUC1 ≥9400 mg × h per liter 5.56 2.19-15.62 .0006 
 Age, y 1.06 1.02-1.10 .004 

OR, odds ratio.

*

Final model includes significant covariates in the multivariate analysis.

Close Modal

or Create an Account

Close Modal
Close Modal